348 Participants Needed

Blinatumomab + Chemotherapy for Leukemia

Recruiting at 143 trial locations
Age: 18+
Sex: Any
Trial Phase: Phase 3
Sponsor: National Cancer Institute (NCI)
Must be taking: TKIs, Steroids
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial
Breakthrough TherapyThis drug has been fast-tracked for approval by the FDA given its high promise

What You Need to Know Before You Apply

What is the purpose of this trial?

This phase III trial compares the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the same treatment plus blinatumomab. Blinatumomab is a Bi-specific T-Cell Engager ('BiTE') that may interfere with the ability of cancer cells to grow and spread. The information gained from this study may help researchers determine if combination therapy with steroids, TKIs, and blinatumomab work better than the standard of care.

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications. However, it does mention that patients should not have received chemotherapy for B-ALL, except for up to five days of certain medications like hydroxyurea or steroids before starting the trial.

Is Blinatumomab safe for use in humans?

Blinatumomab has been tested in various clinical trials and is generally considered safe, but it can cause some serious side effects like cytokine release syndrome (a severe immune reaction) and neurological issues (problems with the brain and nerves). These side effects are usually manageable with proper medical care.12345

What makes the drug Blinatumomab unique for treating leukemia?

Blinatumomab is unique because it is a bispecific T-cell engager that targets CD19 on leukemia cells and activates T-cells to destroy them, offering a novel approach compared to traditional chemotherapy. It is administered through continuous 28-day infusion cycles, which is different from standard chemotherapy schedules.26789

What data supports the effectiveness of the drug Blinatumomab in treating leukemia?

Blinatumomab has been shown to improve survival and complete remission rates in patients with relapsed or refractory acute lymphoblastic leukemia (ALL) compared to standard chemotherapy. In clinical trials, patients treated with Blinatumomab had a median survival of 7.7 months versus 4.0 months with standard chemotherapy, and a higher complete remission rate of 34% compared to 16% with standard treatment.210111213

Who Is on the Research Team?

YO

Yishai Ofran

Principal Investigator

ECOG-ACRIN Cancer Research Group

Are You a Good Fit for This Trial?

Adults aged 18-75 with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia (ALL) can join this trial. They should be in decent physical shape, not pregnant or breastfeeding, and willing to use contraception. People with active brain involvement by leukemia, unstable epilepsy, other cancers, or those who have already started certain treatments for ALL are excluded.

Inclusion Criteria

AST(SGOT)/ ALT(SGPT) =< 2 X the institutional upper limit of normal (ULN)
My liver enzymes are within twice the normal limit.
Any major side effects from my previous treatments have gone away.
See 29 more

Exclusion Criteria

Patients must not expect to conceive or father children by using accepted and effective method(s) of contraception or by abstaining from sexual intercourse from the time of step 1 registration, while on study treatment, and until at least six months after the last dose of study treatment
Patient must not be pregnant or breast-feeding
My epilepsy is stable and does not need treatment.
See 6 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Pre-Induction

Patients receive prednisone and a tyrosine kinase inhibitor (TKI) for 21 days

3 weeks
1 visit (in-person)

Induction Therapy

Patients receive induction therapy with either chemotherapy or blinatumomab, along with steroids and TKI

15 weeks
Multiple visits (in-person)

Re-Induction

Patients who remain MRD positive receive re-induction therapy based on their initial treatment arm

4-8 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

Up to 10 years
Every 3 months for 2 years, every 6 months for years 3-5, then annually for years 6-10

What Are the Treatments Tested in This Trial?

Interventions

  • Blinatumomab
  • Cyclophosphamide
  • Cytarabine
  • Dasatinib
  • Dexamethasone
  • Doxorubicin Hydrochloride
  • Mesna
  • Methotrexate
  • Ponatinib Hydrochloride
  • Prednisone
  • Vincristine Sulfate
Trial Overview The study is testing if adding blinatumomabโ€”a cancer cell growth inhibitorโ€”to the usual treatment of chemotherapy, steroids, and a tyrosine kinase inhibitor is more effective for treating ALL. It's a phase III trial where patients receive either standard care or standard care plus blinatumomab.
How Is the Trial Designed?
5Treatment groups
Experimental Treatment
Active Control
Group I: Arm E (steroid, TKI, chemotherapy)Experimental Treatment14 Interventions
Group II: Arm D (steroid, TKI, chemotherapy, immunotherapy)Experimental Treatment12 Interventions
Group III: Arm C (steroid, TKI, chemotherapy, immunotherapy)Experimental Treatment12 Interventions
Group IV: Arm B (steroid, TKI, chemotherapy)Experimental Treatment15 Interventions
Group V: Arm A (steroid, TKI), Single Arm Pre-InductionActive Control9 Interventions

Blinatumomab is already approved in European Union, United States for the following indications:

๐Ÿ‡ช๐Ÿ‡บ
Approved in European Union as Blincyto for:
๐Ÿ‡บ๐Ÿ‡ธ
Approved in United States as Blincyto for:

Find a Clinic Near You

Who Is Running the Clinical Trial?

National Cancer Institute (NCI)

Lead Sponsor

Trials
14,080
Recruited
41,180,000+

Published Research Related to This Trial

Blinatumomab has been approved for treating relapsed or refractory precursor B-cell acute lymphoblastic leukemia (ALL), showing a significant improvement in overall survival and complete remission rates compared to standard chemotherapy, with a median survival of 7.7 months versus 4.0 months for chemotherapy.
In clinical trials, blinatumomab demonstrated a complete remission rate of 34% in Philadelphia chromosome (Ph)-negative ALL and 31% in Ph-positive ALL, while also presenting some adverse events like cytokine release syndrome and neurological issues, although it had fewer cases of neutropenia and infections compared to standard treatments.
FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B-Cell Acute Lymphoblastic Leukemia.Pulte, ED., Vallejo, J., Przepiorka, D., et al.[2019]
Blinatumomab, a bispecific T-cell-engaging antibody, has shown a response rate of 34% to 66% in heavily pretreated children with relapsed/refractory acute lymphoblastic leukemia (R/R-ALL), making it a promising treatment option, especially as a bridge to stem cell transplantation.
Recent randomized controlled trials indicate that blinatumomab leads to a greater reduction in minimal residual disease and improved survival compared to standard treatments, suggesting its potential for frontline use in high-risk patients.
Blinatumomab in Pediatric Acute Lymphoblastic Leukemia-From Salvage to First Line Therapy (A Systematic Review).Queudeville, M., Ebinger, M.[2021]
Blinatumomab significantly improves overall survival in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL), with a median survival of 7.7 months compared to 4.0 months with traditional chemotherapy.
Patients treated with blinatumomab report a higher quality of life and lower financial burden compared to those receiving standard chemotherapy, making it a more cost-effective treatment option.
Impact of blinatumomab on patient outcomes in relapsed/refractory acute lymphoblastic leukemia: evidence to date.Hathaway, L., Sen, JM., Keng, M.[2020]

Citations

FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B-Cell Acute Lymphoblastic Leukemia. [2019]
Blinatumomab in Pediatric Acute Lymphoblastic Leukemia-From Salvage to First Line Therapy (A Systematic Review). [2021]
Impact of blinatumomab on patient outcomes in relapsed/refractory acute lymphoblastic leukemia: evidence to date. [2020]
Blinatumomab: Bridging the Gap in Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia. [2018]
SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. [2023]
The safety of blinatumomab in pediatric patients with acute lymphoblastic leukemia: A systematic review and meta-analysis. [2022]
Clinical applications and safety evaluation of the new CD19 specific T-cell engager antibody construct blinatumomab. [2017]
Blinatumomab as a bridge to further therapy in cases of overwhelming toxicity in pediatric B-cell precursor acute lymphoblastic leukemia: Report from the Israeli Study Group of Childhood Leukemia. [2020]
Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemia. [2020]
10.United Statespubmed.ncbi.nlm.nih.gov
Delivery of Care for Pediatric Patients Receiving Blinatumomab: A Children's Oncology Group Study. [2023]
Blinatumomab: first global approval. [2020]
12.United Statespubmed.ncbi.nlm.nih.gov
Estimating Long-Term Survival of Adults with Philadelphia Chromosome-Negative Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia Treated with Blinatumomab Using Historical Data. [2021]
Population Pharmacokinetics of Blinatumomab in Pediatric and Adult Patients with Hematological Malignancies. [2021]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of ServiceยทPrivacy PolicyยทCookiesยทSecurity